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Abstract Hypertrophic cardiomyopathy (HCM) is a car-
diovascular genetic disease with a varied clinical presen-
tation and phenotype. Although mutations are typically
found in genes coding for sarcomeric proteins, phenotypic
derangements extend beyond the myocyte to include the
extracellular compartment. Myocardial fibrosis is com-
monly detected by histology, and is associated with clin-
ical vulnerability to adverse outcomes. Over the past
decade, the noninvasive visualization of myocardial fibro-
sis by cardiovascular magnetic resonance (CMR) tech-
niques has garnered much interest given the potential
applications toward improving our understanding of path-
ophysiologic mechanisms of disease, as well as diagnosis
and prognosis. Late gadolinium enhancement (LGE) im-
aging techniques are able to detect focal (typically re-
placement) fibrosis. Newer CMR techniques that measure
absolute T1 relaxation time allow the quantification of the
entire range of focal to diffuse (interstitial) fibrosis and
may overcome potential limitations of LGE. This review
will discuss the methodology and current status of these
novel techniques, with a focus on extracellular volume
fraction (ECV). Recent findings describing ECV measure-
ment in HCM will be summarized.
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most common
genetic cardiovascular disorder, with a prevalence of 0.2 %
reported across several regions of the world [1–3], yet current
management strategies lack therapy directly targeting the un-
derlying disease process(es). The genetic basis is currently
attributed to over 1400 unique mutations in at least 11 genes
coding for proteins comprising the sarcomere [4]. Clinically,
the diagnosis is usually determined by the identification of left
ventricular hypertrophy considered unlikely to be caused by
another cardiac or systemic condition [1]. Alternatively,
genotyping may determine the presence of a mutation deemed
pathogenic. The phenotypicmanifestations and clinical course
are heterogeneous, likely reflecting not only the diversity of
mutations, but additional interactions with modifier genes and
environmental influences. The treatment of symptoms such as
angina or dyspnea on exertion hinges on the determination of
left ventricular outflow tract obstruction due to hypertrophied
myocardium and mitral valve systolic anterior motion. Such
obstruction can be palliated with anti-inotropic medication
and with invasive intervention (surgical myectomy or alcohol
ablation of the hypertrophied septum) if symptoms remain
refractory to maximal medical therapy. Heart transplantation
is also available for those who develop severe heart failure.
While HCM is also associated with malignant arrhythmias
and sudden death, those identified as higher risk can be treated
with implantable defibrillator therapy [1]. However, risk strat-
ification remains an imprecise science, with infrequent appro-
priate defibrillator discharge rates [5] accompanying the re-
duction in population risk. There is a clinical need to move
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beyond palliation and risk reduction and target fundamental
disease pathways.
Myocardial fibrosis is increasingly recognized as an intrin-
sic phenotype of HCM. Although mutations are typically
located in genes coding for sarcomeric proteins, phenotypic
derangements extend beyond the myocyte to include the
extracellular compartment. Indeed, the 2010 National Heart
Lung and Blood Institute HCMWorking Group [6] noted the
lack of data regarding “extra-cardiomyocyte manifestations of
HCM” and called for research that would identify and char-
acterize mechanisms mediating fibrosis and remodeling. The
advent of cardiovascular imaging techniques capable of visu-
alizing myocardial fibrosis permits routine, noninvasive char-
acterization of the interstitial space previously limited to bi-
opsy and postmortem analysis. Such information would not
only improve the understanding of fundamental disease path-
ogenesis, but potentially illuminate therapeutic targets. This
article will briefly review the histopathologic characterization
of fibrosis in HCM, CMR late gadolinium enhancement de-
tection of macroscopic fibrosis and its limitations, and then
focus on emerging CMR T1 quantification techniques. which
can detect the entire spectrum of fibrosis from focal to diffuse.
Finally, we will summarize recent data characterizing ECV
among those with HCM.
Myocardial Fibrosis in Hypertrophic Cardiomyopathy
Myocardial fibrosis is commonly observed in hypertrophic
cardiomyopathy, and has been associated with a range of
clinical outcomes. There are various forms of such fibrosis,
often categorized as replacement and interstitial. Replacement
fibrosis refers to the accumulation of collagen where myocyte
damage and/or necrosis has occurred [7, 8], and may be focal
or diffuse. Interstitial fibrosis occurs more diffusely through-
out the extracellular space of the myocardium, although it can
form along perivascular bundles as well [7, 8]. The mecha-
nisms driving interstitial fibrosis in HCM are incompletely
understood, but are thought to be mediated in part by
transforming growth factor β1, which triggers the production
of extracellular matrix proteins [9]. Although precise defini-
tions of replacement or interstitial fibrosis may vary somewhat
according to the method of detection (eg, histology vs imag-
ing), derangement of the extracellular compartment has been
increasingly recognized as a predictor of outcomes including
sudden death, ventricular arrhythmias, and heart failure. Basso
et al [10] and Shirani et al [11] both demonstrated a high
prevalence of fibrosis detected at autopsy among young pa-
tients who suffered sudden death. In the latter study, qualita-
tive assessment of interstitial collagen was performed using
picrosirius red (a collagen specific stain) as well as quantita-
tive collagen volume fraction determination by semi-
automated image analysis techniques. Of note, areas of
disorganized myocytes (termed myocardial disarray) were
also observed and quantified. Varnava et al also described
similar findings among those with end-stage heart failure [12].
Given the invasive nature of histology for fibrosis detection
and quantification, the ability of noninvasive imaging
methods to visualize extracellular compartment expansion
has garnered much interest. Various non-CMR modalities
for such detection have been previously reviewed [13].
Noninvasive Detection of Focal Fibrosis in HCM
Late gadolinium enhancement (LGE) imaging techniques uti-
lize gadolinium contrast agents, which distribute preferential-
ly to myocardial regions containing extracellular compartment
expansion following a bolus. Although initially used for de-
tection of myocardial infarction (dense regions of replacement
fibrosis confirmed by robust histologic validation), LGE tech-
niques were also found to identify atypical signal patterns
thought to represent scar of nonischemic etiology. Among
those with HCM, Choudhury et al [14] described patchy
patterns of multiple foci of abnormal LGE signal in 17 of 21
patients. The histologic validation of atypical LGE has been
less robust compared with that of myocardial infarction, but
small studies have provided some corroboration. Moon et al
[15] demonstrated high correlation between areas of LGE and
scar by histology in a single heart obtained following heart
transplantation. A larger series by Moravsky et al [16] dem-
onstrated good correlation between quantitative assessment of
histologic fibrosis and LGE inmyocardial samples obtained at
the time of septal myectomy surgery. Reassuringly, CMR
identification of LGE has been linked with important patient
outcomes of sudden death, arrhythmia, and heart failure in
multiple centers [17–20].
There are, however, limitations of the LGE technique that
are important to consider, especially in the HCM arena [21].
Given the high prevalence of LGE among those with HCM
[22], there is a clinical need to move beyond binary reporting
of its presence or absence and to quantify precisely its extent.
There is no universally accepted strategy for such quantifica-
tion, in part due to the variety of algorithms proposed—each
of which have strengths and weaknesses [23] (eg, manual
tracing vs full-width at half-maximum vs various standard
deviations beyond a normal region of interest). In addition,
the heterogeneous nature of fibrosis accumulation in HCM
ranging from focal to diffusemay preclude the availability of a
completely “normal” region of myocardium to act as a refer-
ence. Other factors leading to variability in quantification may
be considered by category, including: image acquisition pa-
rameters (spatial resolution, slice thickness, segmented vs
single shot imaging, phase sensitive vs magnitude reconstruc-
tion, and the time elapsed between bolus and LGE imaging),
patient parameters (heart rate, gadolinium concentration
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Fig. 1 (Adapted from Wong et al [32], with permission from Lippincott
Williams & Wilkins - Wolters Kluwer Health). Measurement of pre and
postcontrast T1 in an individual with normal ECV. Short axis imaging at
varying time points (precontrast images top row, postcontrast images
bottom row) along with the corresponding fitting curves used to derive
absolute T1measurement. Calculations are performed at the pixel level to
generate pre and postcontrast T1 maps
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dependence on weight based dosing, and glomerular filtration
rate), and also contrast agent characteristics (protein binding,
relaxivity, and dosing strategy—especially important, given a
nonlinear relationship between signal intensity and gadolini-
um concentration).
Recent advances in CMR imaging which allow for extracel-
lular volume fraction (ECV) quantification may offer solutions
to many of these limitations. ECV takes advantage of absolute
measurement of T1 relaxation time, compared with relative
differences in T1 weighted signal intensity for LGE imaging,
and can detect the entire range of fibrosis from focal to diffuse.
Noninvasive Detection of Diffuse Fibrosis in HCM
The development of CMR techniques which perform rapid,
serial experiments by which the absolute T1 time of tissue,
and subsequently the extracellular volume fraction, may be
derived has generated considerable interest. A brief discussion
of terminology in this rapidly evolving field is relevant to this
review. Native T1 refers to myocardial T1 measurement with-
out the use of gadolinium contrast agents, and reflects myo-
cardial characteristics affecting both the cellular and extracel-
lular compartment [24••]. For example, shortened native T1 is
observed due to intracellular lipid accumulation in Anderson-
Fabry disease [25, 26], a phenocopy of HCM. Postcontrast T1
refers to T1 measurement at a time point after gadolinium
administration (typically bolus), which again may reflect
myocardial properties. However, postcontrast T1 may be
confounded by variations in the precise time of measurement,
body weight, and corresponding contrast dose, rate of gado-
linium clearance (dependent on renal function), and hemato-
crit [27••]. Finally, the extracellular volume fraction (ECV)
technique directly measures the proportion of myocardium
occupied by extracellular space—typically a marker of fibro-
sis in the absence of edema or amyloid deposition. ECV
exploits the extracellular nature of gadolinium and measures
myocardial uptake of contrast relative to plasma since gado-
linium and plasma equilibrate during slow renal washout. The
proportion of uptake can be computed by the change in
relaxivity (inverse of T1) for myocardium and plasma since
the change in relaxivity linearly relates to gadolinium concen-
tration. Plasma change in relaxivity is derived from blood
change in relaxivity by multiplying the latter by (1-
hematocrit). Because the HCM phenotype is most noted for
extracellular fibrosis (as opposed to intracellular derange-
ment), and because of inherent variability in postcontrast T1
measurement, this article will focus on ECVmeasurement as a
marker of extracellular matrix expansion and fibrosis.
There are various methods for absolute T1 measurement,
which have coalesced along 3 main techniques which involve
either inversion recovery or saturation recovery experiments:
Modified Look-Locker Inversion (MOLLI) recovery [28],
Shortened MOLLI (ShMOLLI) [29], and Saturation
Recovery Single-shot Acquisition (SASHA) [30]. A detailed
description and comparison of these techniques is beyond the
Fig. 2 CMR images of a patient with hypertrophic cardiomyopathy. a
Four-chamber steady state free precession (SSFP) image demonstrating
asymmetric septal hypertrophy. b Three-chamber SSFP image. c Mid-
ventricular short axis LGE image ~15 minutes postgadolinium contrast
showing focal LGE in the vicinity of the right ventricular insertion point.
d Precontrast T1 map. e postcontrast T1map~20 minutes postgadolinium
contrast. f ECV map calculated using the T1 data and hematocrit. The
horizontal dashed white line notes the color range of the upper limit of
normal of ECV (~29.5 % at our center). The black arrows point to the
anterior septal region where more diffuse fibrosis is identified, which was
not as readily apparent on the LGE image (panel (c). Note: panels c, d, e, f
are the same short axis slice
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scope of this article, although a cogent discussion was recently
published [31]. Figure 1 demonstrates a sample set of imaging
experiments used to obtain myocardial and blood T1 mea-
surement in a normal individual. Once a method for T1
measurement is set, motion-correction of serial imaging ex-
periments and then mapping may be performed on a pixel-
wise basis so that a T1 map is generated such that each pixel
reflects the absolute T1 value of that region [27••].
Using T1 values of myocardium and blood, obtained pre-
and postcontrast, ECV measurement may be performed to
obtain an estimate of the % fraction of extracellular space in
the tissue of interest. In brief, ECV=λ * (1–hematocrit) where
λ is the partition coefficient for gadolinium in the myocardium
and blood pool, which is equal to the ratio of the correspond-
ing change in relaxivity (ΔR) before and after contrast admin-
istration (λ=ΔR1myocardium / ΔR1blood, ΔR1=1/T1postGd–
1/T1preGd). A more detailed description of the calculation
steps has been previously described [32]. Furthermore, T1
mapping data may be used to compute ECV maps. Figure 2
demonstrates a representative HCM imaging case from our
center where T1 maps are acquired pre and postcontrast, and
used (along with the hematocrit) to produce an ECV map.
Motion correction algorithms maximize image coregistration
required for pixelwise parametric maps of T1 and ECV [33].
The histologic validation of ECV and diffuse myocardial
fibrosis in HCM has been described by several centers. Flett
et al [34] reported excellent correlation (R2=0.86) between
ECVand collagen volume fraction in a cohort of patients with
either aortic stenosis or hypertrophic cardiomyopathy.
Fontana et al [35] and White et al [36] both demonstrated
good correlations with quantitative histology using variations
on the ECV technique in a wider spectrum of patients with
aortic stenosis, hypertrophic cardiomyopathy, amyloid, chron-
ic myocardial infarction. Miller et al also described robust
agreement in an elegant, comprehensive study of whole heart
validation of ECV against histology [37] in hearts explanted
from humans at the time of heart transplantation. Validation of
ECV against longitudinal outcomes prediction among those
with HCM has not been published to date, although our group
has demonstrated incremental prognostic value of ECV for
clinical outcomes in a large cohort, which did not include
HCM [32, 38].
While such strong validation data are certainly encourag-
ing, several words of caution regarding interpretation of ECV
data should be mentioned. It is important to note that ECV
reflects measurement of the entire extracellular space and does
not inform regarding potential variables of interest such as the
state of collagen cross-linking or extent of signal due to
myocardial disarray. Furthermore, heterogeneity remains re-
garding standardization of the measurement technique (plat-
form, choice of gadolinium chelate, etc). Fortunately, a T1
mapping working group has convened to produce a recent
consensus document [24••] summarizing agreement and
challenges in the field, with plans for further updates as the
field continues to mature.
Current Studies of ECV in HCM
Already, several centers have begun exploring the role of ECV
as a novel imaging biomarker of diffuse myocardial fibrosis
among those with HCM. From a diagnostic standpoint,
Ugander et al [39], Sado et al [40], and Kellman et al [41],
all demonstrated the ability of abnormally elevated ECV
measurement to discriminate between myocardial regions
(and individuals) of health vs disease. Our group has observed
a preliminary association between ECV and BNP [42], of
interest given the recent observation that BNP may be a
relevant HCM disease severity marker [43]. Also, Ho et al
[8] report the observation that ECV is abnormally elevated in
sarcomeric HCM mutation carriers without left ventricular
hypertrophy, a finding with implications both for diagnosis
as well as assessment of disease response to anti-fibrotic
therapies. Finally, we await the results of the large observa-
tional study of HCM recently organized by Kramer and
Neubauer to characterize prognostic markers in HCM, includ-
ing T1mapping markers of diffuse fibrosis (ClinicalTrials.gov
identifier NCT01915615).
Conclusions
Myocardial fibrosis, both focal replacement as well as diffuse
interstitial types, is prevalent in HCM and related to adverse
clinical outcomes. The noninvasive capability of contrast
enhanced CMR imaging techniques allows for identification
and serial monitoring of this important disease phenotype. The
advent of absolute T1 measurement techniques permit the
measurement of extracellular volume fraction, which can
quantify the entire range of fibrosis from diffuse to focal,
and may overcome some limitations of current late gadolini-
um enhancement based techniques. The application of ECV
to the study of HCM is nascent, and much further work
remains to be done to determine the role of ECV in diag-
nosis, prognosis, and assessment of disease response to
targeted therapy.
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